钻研25年致力于提升谷胱甘肽

RiboCeine&trad;

有效促进谷胱甘肽生成背后的突破性分子

科学家与医生发现谷胱甘肽已有数十年,谷胱甘肽由人体自行制造,主要功能在保护细胞、清除毒素。然而,在氧化压力下,人体内谷胱甘肽含量会降低,此外随着年龄逼近40,身体制造谷胱甘肽的能力也随之减弱,年龄愈大,制造能力就越差。多年来,研究医学的科学家一直想要找出能够有效提升人体谷胱甘肽含量的方法,之前N-乙酰半胱氨酸 (NAC) 是唯一能够增加人体半胱氨酸供给的唯一补充品,目的在促进谷胱甘肽生成。但赫伯特‧永泽博士开发出一种革命性分子,那就是RiboCeine,可以有效将半胱氨酸运送到细胞,以便人体自行制造谷胱甘肽。也因此,Max International获得美国专利。

经科学证明之专利技术

RiboCeine是一种独特分子,结合了核糖 (Ribose) 与半胱氨酸 (Cysteine) 这两种人体自行生成的营养物。RiboCeine一经摄取即为人体所吸收,进入血液中,将核糖与半胱氨酸运送到细胞,促进谷胱甘肽生成;其所提供的核糖,是三磷酸腺苷 (ATP) 的一部分,为人体天然养分、能量来源。与其他提升谷胱甘肽的方式相比,RiboCeine经测试证明成效明显高出许多。美国国家卫生研究院 (National Institutes of Health, NIH) 或其他科学基金会补助了超过23篇以RiboCeine为主题的科学研究,并刊登在同侪审查期刊当中。

有关核糖–半胱氨酸 (Ribose-Cysteine) 之影响的独立研究

注意:下列连结将会带您离开本网页,并前往第三方研究网站。

1.Saltman A.E.D-ribose-L-cysteine supplementation enhances wound healing in a rodent model.Am J Surg.2015, 210, 153-158.

2.Kader, T.; Porteous C.M.; Williams M.A.J.A.; Gieseg, S.P.; McCormick, S.P.A.Ribose-cysteine increases glutathione-based antioxidant status and reduces LDL in human lipoprotein(a) mice.Atherosclerosis.2014, 237, 725-733.

3.Jurkowska, H.; Uchacz, T.; Roberts, J.; Wrobel, M.Potential therapeutic advantage of ribose-cysteine in the inhibition of astrocytoma cell proliferation.Amino Acids,2011, 41, 131-139.

4.Heman-Ackah, S.E.; Juhn, S.K.; Huang, T.C.; Wiedmann, T.S.A combination antioxidant therapy prevents age-related hearing loss in C57BL/6 mice.Otolaryngology-Head and Neck Surgery, 2010,143, 429-434.

5.Oz, H.S.; Chen, T.S.; Nagasawa, H.,Comparative efficacies of 2 cysteine prodrugs and a glutathione delivery agent in a colitis model.Translational Research,, 150(2), 122-129., 150(2), 122-129.

6.Lucas Slitt, A.M.; Dominick, P.K.; Roberts, J.C.; Cohen, S.D.Effect of Ribose Cysteine Pretreatment on Hepatic and Renal Acetaminophen Metabolite Formation and Glutathione Depletion.Basic Clin. Pharmacol. Toxicol.,2005, 96 (6), 487-94.

7.Waldron, C.A.; Vannais, D.B.; Ueno A.M.A role for long-lived radicals (LLR) in radiation-induced mutation and persistent chromosomal instability: counteraction by Ascorbate and RibCys but not DMSO.Mutation Research.2004, 551, 255-265.

8.Lenarczyk, M.; Ueno, A.; Vannais, D.B.; Kraemer, S.; Kronenberg, A.; Roberts, J.C.; Tatsumi, K.; Hei, T.K.; Waldron, C.A.The "Pro-drug" RibCys Decreases the Mutagenicity of High-LET Radiation in Cultured Mammalian Cells. Radiation Research,2003, 160, 579-583.

9.Wilmore, B.H.; Cassidy, P.B.; Warters, R.L.; Roberts, J.C.Thiazolidine Prodrugs as Protective Agents against y-Radiation-Induced Toxicity and Mutagenesis in V79 Cells.J. Med. Chem.,, 44(16), 2661-2666., 44(16), 2661-2666.

10.Lucus, A.M.; Henning G.; Dominick, P.K.; Whiteley, H.E.; Roberts, J.C.; Cohen, S.D.Ribose Cysteine Protects Against Acetaminophen-Induced Hepatic and Renal Toxicity.Toxicologic Pathology,2000, 28(5), 697-704.

11.Roberts, J.C.; Phaneuf, H.L.; Dominick, P.K.; Wilmore, B.H.; Cassidy, P.B.Biodistribution of [35S] - Cysteine and Cysteine Prodrugs: Potential Impact on Chemoprotection Strategies.J. Labelled Cpd. Radiopharm.,1999all.riboceine.study1.51

12.Roberts, J.C.; Phaneuf, H.L.; Szakacs, J.G.; Zera, R.T.; Lamb, J.G.; Franklin, M.R.Differential Chemoprotection against Acetaminophen-Induced Hepatotoxicity by Latentiated L-Cysteines.Chem. Res. Toxicol.,1998, 11, 1274-1282.

13.Bantseev, V.; Bhardwaj, R.; Rathbun, W.; Nagasawa, H.T.; Trevithick, J.R.Antioxidants and Cataract: (Cataract Induction in Space Environment and Application to Terrestrial Aging Cataract).Biochem. Mol. Bio. Intl.,1997, 42, 1189-1197.

Roberts, J.C.; Koch, K.E.; Detrick, S.R.; Warters, R.L.; Lubec G.14.Thiazolidine Prodrugs of Cysteamine and Cysteine as Radioprotective Agents.Radiation Research,1995, 143, 203-213.

15.Carroll, M.P.; Zera, R.T.; Roberts, J.C.; Schlafmann, S.E.; Feeny, D.A.; Johnston, G.R.; West, M.A.; Bubrick, M.P.Efficacy of Radioprotective Agents in Preventing Small and Large Bowel Radiation Injury.Dis. Colon Rectum,1995, 38(7), 716-722.

16.Roberts, J.C.;Francetic, D.J.; Zera, R.T.Chemoprotection against Cyclophosphamide-Induced Urotoxicity: Comparison of Nine Thiol Protective Agents.AntiCancer Research,1994, 14, 389-396.

17.Rowe, J.K.; Zera, R.T.; Madoff, R.D.; Fink, A.S.; Roberts, J.C.; Johnston, G.R.; Freeney, D.A.;Young, H.L.; Bubrick, M.P.Protective Effect of RibCys Following High-Dose Irradiation of the Rectosigmoid.Dis. Colon Rectum,1993, 36(7), 681-687.

18.Roberts, J.C.; Charyulu, R. L.; Zera, R.T.; Nagasawa, H.T.Protection Against Acetaminophen Hepatotoxicity by Ribose-Cysteine (RibCys).Pharmacology & Toxicology,1992, 70, 281-285.

19.Roberts, J.C.; Francetic, D.J.Mechanisms of Chemoprotection by RibCys, a Thiazolidine Prodrug of L-cysteine.Med. Chem. Res.,1991, 1, 213-219.

20.Roberts, J.C.; Francetic, D.J.Time course for the elevation of glutathione in numerous organs of L1210-bearing CDF1 mice given the L-cysteine prodrug, RibCys.Toxicology Letters,1991, 59, 245-251.

21.Roberts, J.C.; Francetic, D.J.; Zera, R.T.L-cysteine prodrug protects against cyclophosphamide urotoxicity without compromising therapeutic activity.Cancer Chemotherapy and Pharmacology,1991, 28, 166-170.

22.Roberts, J.C.; Nagasawa, H.T.; Zera, R.T.; Fricke, R.F.; Goon, D.J.W.Prodrugs of L-Cysteine as Protective Agents against Acetaminophen-Induced Hepatotoxicity. 2-(Polyhydroxyalkyl)- and 2-(Polyacetoxyalkyl)thiazolidine-4(R)-carboxylic Acids.. J. Med. Chem.,1987, 30, 1891-1896.

请自订您的销售地区及语言偏好

地区/地区

cross-img
  • Submit
shadow